Pay to Marwadi

Company Profile

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE636.75-7.1 (-1.1 % )
PREV CLOSE (Rs.) 643.85
OPEN PRICE (Rs.) 644.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1651
TODAY'S LOW / HIGH (Rs.)635.20 647.35
52 WK LOW / HIGH (Rs.)427.05 767
NSE641.50 -3.95 (-0.61 % )
PREV CLOSE(Rs.) 645.45
OPEN PRICE (Rs.) 645.45
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 641.50 (137 )
VOLUME 47789
TODAY'S LOW / HIGH(Rs.) 635.15 649.00
52 WK LOW / HIGH (Rs.)468.6 768

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.94
TTM EPS (Rs.) 14.99
P/E Ratio 42.38
Book Value (Rs.) 78.60
Face Value (Rs.) 1
MCap (Rs. in Mn) 161699.66
Price/Earning (TTM) 38.04
Price/Sales (TTM) 14.11
Price/Book (MRQ) 8.08
PAT Margin (%) 32.50
ROCE (%) 34.48
Incorporation Year : 2018

Management Info :

Annaswamy Vaidheesh - Chairman V Prasada Raju - Managing Director

Registered Office :

Address : 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri East, Chakala Midc,
Mumbai,
Maharashtra-400093

Phone : 040 - 2354 9414 / 1142 /3311

Website : www.suvenpharm.com

Registrar's Details : K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
01Mar03-01-2024$Suven Pharmaceuticals shines on planning to merge Cohance with itself Suven Pharmaceuticals shines

Suven Pharmaceuticals is currently trading at Rs. 678.65, up by 47.75 points or 7.57% from its previous closing of Rs. 630.90 on the BSE.

The scrip opened at Rs. 653.95 and has touched a high and low of Rs. 712.00 and Rs. 646.00 respectively. So far 1659278 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.00 on 04-Jan-2024 and a 52 week low of Rs. 375.00 on 05-Apr-2023.

Last one week high and low of the scrip stood at Rs. 712.00 and Rs. 625.10 respectively. The current market cap of the company is Rs. 17281.14 crore.

The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 26.09% and 13.92% respectively.

Suven Pharmaceuticals has proposed scheme of amalgamation to merge Cohance Lifesciences (Cohance) with itself. This marks a pivotal moment in Suven's journey, underscoring its commitment to scaling, ensuring consistent earnings, fortifying its financial standing, and advancing towards forging leadership in the integrated CDMO space.

Cohance is a leading CDMO and Merchant API platform with global leadership in select low-mid volume molecules as well as unique capabilities in the form of its antibody drug conjugates (ADC) platform. 

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.


Suven Pharmaceuticals is currently trading at Rs. 678.65, up by..
29Feb02-29-2024$Amalgamation Amalgamation
Scheme of Arrangement Inter alia, have considered and approved a scheme of amalgamation of Cohance Lifesciences Limited (?Transferor Company?) into and with the Company and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder, SEBI Master Circular dated 20 June 2023 bearing reference number SEBI/HO/CFD/POD- 2/P/CIR/2023/93 and all amendments thereto (?Scheme?). (Transferor Company and Transferee Company collectively referred to as the ?Amalgamating Companies?). Pursuant to the proposed Scheme, equity shares of the Company shall be issued to the shareholders of the Transferor Company in accordance with the Share Exchange Ratio (as defined below), which would be listed on the BSE Limited and the National Stock Exchange of India Limited (collectively referred to as ?Stock Exchanges?). The Scheme is subject to the receipt of applicable approvals, including approvals from the respective jurisdictional Hon?ble National Company Law Tribunal, SEBI, Department of Pharmaceuticals (if such approval is required pursuant to applicable laws), Stock Exchanges and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary. The Appointed Date for the Scheme shall be the Effective Date (as defined below in this paragraph), or such other date as may be approved by the board of directors of the Amalgamating Companies. Further, the effective date for the Scheme shall be the opening business hours of the first day of the month immediately succeeding the month in which the last of the conditions to the effectiveness of the Scheme, as set out in the Scheme are fulfilled, obtained or otherwise duly waived (?Effective Date?). Further, in connection with the proposed amalgamation contemplated under the Scheme (?Proposed Amalgamation?), the promoter of the Transferor Company (i.e., Jusmiral Holdings Limited) has also agreed to indemnify the Transferee Company with respect to certain matters.
Scheme of Arrangement Inter alia, have considered and approved..
29Feb02-29-2024$Scheme of Arrangement Scheme of Arrangement
Scheme of Arrangement Inter alia, have considered and approved a scheme of amalgamation of Cohance Lifesciences Limited (?Transferor Company?) into and with the Company and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder, SEBI Master Circular dated 20 June 2023 bearing reference number SEBI/HO/CFD/POD- 2/P/CIR/2023/93 and all amendments thereto (?Scheme?). (Transferor Company and Transferee Company collectively referred to as the ?Amalgamating Companies?). Pursuant to the proposed Scheme, equity shares of the Company shall be issued to the shareholders of the Transferor Company in accordance with the Share Exchange Ratio (as defined below), which would be listed on the BSE Limited and the National Stock Exchange of India Limited (collectively referred to as ?Stock Exchanges?). The Scheme is subject to the receipt of applicable approvals, including approvals from the respective jurisdictional Hon?ble National Company Law Tribunal, SEBI, Department of Pharmaceuticals (if such approval is required pursuant to applicable laws), Stock Exchanges and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary. The Appointed Date for the Scheme shall be the Effective Date (as defined below in this paragraph), or such other date as may be approved by the board of directors of the Amalgamating Companies. Further, the effective date for the Scheme shall be the opening business hours of the first day of the month immediately succeeding the month in which the last of the conditions to the effectiveness of the Scheme, as set out in the Scheme are fulfilled, obtained or otherwise duly waived (?Effective Date?). Further, in connection with the proposed amalgamation contemplated under the Scheme (?Proposed Amalgamation?), the promoter of the Transferor Company (i.e., Jusmiral Holdings Limited) has also agreed to indemnify the Transferee Company with respect to certain matters.
Scheme of Arrangement Inter alia, have considered and approved..
23Feb02-23-2024$USFDA completes inspections at Suven Pharmaceuticals’ API, Formulations facilities USFDA completes inspections

US Food & Drug Administration (US FDA) has completed Pre-Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections at Suven Pharmaceuticals’ Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India. The inspections were conducted from February 12, 2024, to February 23, 2024. No Form 483 has been issued as a result of the inspection.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.


US Food & Drug Administration (US FDA) has completed Pre-Ap..
06Dec12-06-2023$Suven Pharmaceuticals informs about disclosure Suven Pharmaceuticals inform

Suven Pharmaceuticals has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund.

The above information is a part of company’s filings submitted to BSE.

Suven Pharmaceuticals has informed that the exchange has receiv..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit523.634326.02
Gross Profit 695.02 5793.93
Operating Profit 821.056276.3
Net Sales 2128.2713300.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
NGL Fine-Chem (BSE)
 2621.00 (5.75%)
M.Cap ( in Cr)
1643.73
Glaxosmithkline Phar (BSE)
 2079.80 (7.06%)
M.Cap ( in Cr)
35072.98
TTK Healthcare (BSE)
 1591.35 (5.77%)
M.Cap ( in Cr)
2289.54
Cipla (BSE)
 1398.80 (3.79%)
M.Cap ( in Cr)
113035.30
Torrent Pharma (BSE)
 2685.00 (1.85%)
M.Cap ( in Cr)
90723.68
Shareholding Pattern More
PROMOTERS 50.1 %
NON-INSTITUTION 23.1 %
MUTUAL FUNDS/UTI 15.26 %
FI/BANKS/INSURANCE 1.57 %
GOVERNMENT 0.01 %
FII 0 %
MF HOLDINGS More
F & O Quotes